A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ICOS Corporation
• Treatments: Antibodies; Antibodies, Monoclonal

Criteria

Inclusion Criteria:

• Current diagnosis of community-acquired pneumonia.

• Evidence of systemic inflammatory response to infection.

Exclusion Criteria:

• Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.

• Presence of organ failure.